Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Inclusion Criteria : * Aged 6 months to 8 years but not yet 9 years on the day of inclusion. * Subject is healthy, as determined by medical history. * Institution Review Board (IRB)-approved informed assent form signed by eligible subject (if required by local regulations) and/or an IRB-approved informed consent form signed by the subject's parent(s) or legal representative (and by an independent witness if required by local regulations). * Parent or legal guardian willing and able to attend (bring subject) to all scheduled visits and comply with all trial procedures. Exclusion Criteria : * Participation in another clinical trial in the 4 weeks preceding the trial vaccination. * Planned participation in another clinical trial during the present trial period. * Personal or family history of Guillain-Barré Syndrome. * Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. * Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or a vaccine containing the same substances. * Chronic illness at a stage that could interfere with trial conduct or completion * Received blood or blood-derived products in the previous 3 months. * Any vaccination in the 4 weeks preceding or following the trial vaccinations (Subjects can take standard childhood vaccination(s) following Visit 3 blood draw). * Known current human immunodeficiency virus (HIV), hepatitis B (HBsAg) or hepatitis C infection or seropositivity. * Known thrombocytopenia or bleeding disorder contraindicating IM vaccination. * Acute medical illness, with or without fever, within the last 72 hours or an oral temperature ≥ 37.5 °C (99.5 °F) or rectal temperature of ≥ 38°C (100.4 °F) at the time of enrollment. * History of seizures. * Received antibiotics therapy within 72 hours preceding the trial vaccination. * Received any allergy shots in the 7-day period preceding trial vaccination and/or scheduled to receive any allergy shots in the 7-day period after trial vaccination. * Any condition, which in the opinion of the investigator would pose a health risk to the participant.